Trading-Stocks.de

Healthcare | Biotechnology | USA
Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition

Shares of Sarepta Therapeutics surge after the company announces an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy shows promising results.

...

Shares of Sarepta Therapeutics (SRPT - Get Report) surged nearly 10% on Wednesday after the company announced an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy showed promising results.

...

Sarepta's early stage study and trial of its MYO-101 treatment showed a benefit for patients with a lesser-known, severe form of muscular dystrophy that primarily affects shoulders and hips.

...

https://www.thestreet.com/investing/stoc...l-14880311

Sarepta Therapeutics verlieren heute gute 50%:

Is Sarepta Stock Worth Buying After the 50% Plunge? Analyst Weighs In


Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that. Case in point: Sarepta Therapeutics (SRPT) shares tanked ~50% in Friday's trading session, following the release of underwhelming clinical trial results.

Specifically, top-line data from the first part study evaluating SRP-9001, the company's microdystrophin gene therapy, for Duchenne muscular dystrophy (DMD) patients, failed to show a statistically meaningful improvement when compared to the placebo.


...

https://finance.yahoo.com/news/sarepta-s...53113.html